How AI is supercharging drug development
TL;DR
Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research. Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%.
Nauti's Take
For small teams in regulated fields, this is not a cue to add automation indiscriminately. Check which preclinical steps are actually accelerated by reliable models and where human validation still drives cost and risk.
Because the story rests on a single survey, it is too early to treat this as solid ROI proof for software budgets.
Sources